Core Laboratories (CLB) Holdings Increased by Jane Street Group LLC

Jane Street Group LLC increased its holdings in Core Laboratories (NYSE:CLB) by 902.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 27,785 shares of the oil and gas company’s stock after acquiring an additional 25,014 shares during the period. Jane Street Group LLC owned approximately 0.06% of Core Laboratories worth $1,658,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Eukles Asset Management acquired a new position in Core Laboratories during the fourth quarter worth $27,000. Bremer Trust National Association acquired a new position in Core Laboratories during the fourth quarter worth $43,000. Financial Gravity Companies Inc. acquired a new stake in shares of Core Laboratories in the fourth quarter valued at $57,000. Captrust Financial Advisors raised its stake in shares of Core Laboratories by 20.4% in the fourth quarter. Captrust Financial Advisors now owns 1,856 shares of the oil and gas company’s stock valued at $111,000 after acquiring an additional 314 shares in the last quarter. Finally, Pendal Group Ltd acquired a new stake in shares of Core Laboratories in the fourth quarter valued at $137,000.

NYSE:CLB traded down $0.14 during trading hours on Friday, hitting $73.83. The company’s stock had a trading volume of 819,182 shares, compared to its average volume of 420,039. The firm has a market capitalization of $3.27 billion, a PE ratio of 32.38, a price-to-earnings-growth ratio of 2.58 and a beta of 1.86. Core Laboratories has a 52-week low of $56.72 and a 52-week high of $130.34. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.25 and a quick ratio of 1.81.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings data on Wednesday, January 30th. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.01). Core Laboratories had a return on equity of 63.86% and a net margin of 11.35%. The firm had revenue of $173.20 million for the quarter, compared to analysts’ expectations of $173.90 million. During the same period in the previous year, the business posted $0.58 EPS. The business’s revenue for the quarter was up 1.8% compared to the same quarter last year. As a group, equities analysts anticipate that Core Laboratories will post 2.08 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 21st. Investors of record on Friday, April 26th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, April 25th.

CLB has been the topic of several analyst reports. Tudor Pickering upgraded Core Laboratories from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. Zacks Investment Research upgraded Core Laboratories from a “hold” rating to a “buy” rating and set a $77.00 price objective on the stock in a research note on Wednesday, April 3rd. Piper Jaffray Companies set a $70.00 price objective on Core Laboratories and gave the company a “hold” rating in a research note on Wednesday, December 26th. UBS Group set a $72.00 price objective on Core Laboratories and gave the company a “hold” rating in a research note on Saturday, February 2nd. Finally, Citigroup reduced their price objective on Core Laboratories from $76.00 to $66.00 and set a “neutral” rating on the stock in a research note on Friday, January 4th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. Core Laboratories has an average rating of “Hold” and a consensus target price of $89.64.

In related news, CAO Kevin Daniels sold 428 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $66.25, for a total transaction of $28,355.00. Following the transaction, the chief accounting officer now owns 352 shares of the company’s stock, valued at $23,320. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.00% of the company’s stock.

WARNING: This news story was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/core-laboratories-clb-stake-raised-by-jane-street-group-llc.html.

Core Laboratories Profile

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

See Also: What is the yield curve?

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.